Quanterix launches blood test to detect early Alzheimer’s disease
Click Here to Manage Email Alerts
Quanterix Corporation announced the launch of LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with signs of early Alzheimer’s disease.
According to a release from Quanterix, the LucentAD test — which is expected to become available to health care providers for use in conjunction with other diagnostic tools — will provide clinicians with a simplified assessment process to determine whether a patient presents with amyloid pathology consistent with AD.
The LucentAD test measures the protein p-Tau 18 and its concentration in both plasma and cerebrospinal fluid, whose presence correlates to amyloid pathology in the brain. LucentAD uses the Simoa p-Tau 181 assay, whose high analytical sensitivity allows for detection of p-Tau 181, which is a low-abundance protein in blood.
“A year ago, Quanterix announced the validation of our laboratory developed test to quantitatively measure p-Tau 181 in plasma as an aid in diagnostic evaluation of Alzheimer’s disease,” Masoud Toloue, CEO at Quanterix, stated in the release. “The launch of Lucent Diagnostics and availability of the LucentAD test expands access to our p-Tau 181 test for health care providers and marks an important step in our goal to help build a global Alzheimer’s disease testing infrastructure.”